Clinical Trials Logo

Emergency Contraception clinical trials

View clinical trials related to Emergency Contraception.

Filter by:

NCT ID: NCT06162611 Recruiting - Clinical trials for Emergency Contraception

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

Start date: November 6, 2023
Phase: Phase 4
Study type: Interventional

Intrauterine devices (IUDs) are highly effective to prevent pregnancy when used for emergency contraception (following unprotected intercourse in the last 3 days), but data are lacking for people who desire an etonogestrel (ENG) contraceptive implant in this situation. This proposal will identify the most effective way to start an implant for emergency contraception using a randomized controlled trial comparing pregnancy risk between those receiving the implant vs. the implant plus oral emergency contraception (EC). Data from this project will inform clinical practice and add another option, the implant, for those desiring a long acting, highly effective contraceptive method when they present for emergency contraception.

NCT ID: NCT04172584 Not yet recruiting - Clinical trials for Emergency Contraception

Awareness & Use of Emergency Contraception

Start date: December 1, 2019
Phase:
Study type: Observational

General objective: To decrease the percentage of unwanted and/or unplanned pregnancies and their consequences on women's reproductive health. Specific objectives: 1. To assess awareness of the study participants about emergency contraception. 2. Determine the percentage of ever use among the participants. 3. To identify factors that affect the awareness and use of emergency contraception among the study participants

NCT ID: NCT03614494 Completed - Clinical trials for Emergency Contraception

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Start date: August 20, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

NCT ID: NCT03395756 Completed - Contraception Clinical Trials

Depot Medroxyprogesterone Acetate as Emergency Contraception

Start date: August 31, 2018
Phase: Early Phase 1
Study type: Interventional

Background: The prevalence of repeat unprotected intercourse after EC use in the same cycle demonstrate the need for more self-bridging emergency contraceptive options. We propose the use of intramuscular Depot Medroxyprogesterone acetate (DMPA) as EC, which has been shown to inhibit follicular activity within 24 hours, and provide on-going contraception via suppression or disruption of ovulation. Objective: The objective of this study is to explore the potential of depot medroxyprogesterone acetate (DMPA) given as a 150-mg intramuscular injection for use as an emergency contraceptive. Study population: Healthy regularly menstruating women aged 18-39 years old will be invited to participate if they fulfill inclusion criteria. The participants will undergo a screening visit during the midluteal phase of their cycle, and will be enrolled if a serum progesterone level is >3ng/ml. Methodology: Participants will be assigned to one of three groups based on leading follicle size. Starting cycle Day 8, transvaginal ultrasounds will be performed to assess the size of the leading follicle. Once the follicle has reached the pre-assigned size, 150 mg IM DMPA will be administered. Blood will be collected for baseline hormonal assays. For 5 consecutive days, daily blood will be drawn for hormonal assays and daily transvaginal ultrasound will be performed to assess for signs of ovulation. The participant will then return for twice weekly progesterone levels for 2 weeks for study completion.

NCT ID: NCT03208985 Completed - Clinical trials for Emergency Contraception

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

LIBRella
Start date: May 23, 2017
Phase: Phase 3
Study type: Interventional

This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.

NCT ID: NCT03120728 Recruiting - Clinical trials for Emergency Contraception

Application for the Etonogestrel/Ethinyl Estradiol Ring

AFTER
Start date: July 10, 2017
Phase: Phase 4
Study type: Interventional

This study is enrolling healthy women ages 18-39yo who are not pregnant or breastfeeding, and are not using hormonal birth control. Initial screening visit will include a blood draw to assess if the participant has recently ovulated. If hormone test indicates ovulation occurred, participant will start the study 8 days after the start of their next menstrual period. On this study visit, vaginal ultrasound will be performed to look the ovaries for follicles. Vaginal ultrasound is then performed approximately every 2 days until the dominant follicle has grown into the size group assigned. When this occurs the participant will place the NuvaRing®, inside the vagina and blood will be drawn for hormone levels. Participant will then return daily the next 5 days (total of 6 daily visits) for vaginal ultrasound and blood draw to assess for signs of ovulation. After the 7th day the ring is in the vagina, the participant will remove the ring from her vagina at home. After removal, there will be twice weekly clinic visits for ultrasound and blood draw until menstrual bleeding occurs. At this point, participation in the study is complete. Participants are compensated for their time.

NCT ID: NCT02078414 Completed - Contraception Clinical Trials

Continued Use of Effective Contraception After Use of Emergency Contraception

Start date: March 2014
Phase:
Study type: Observational

Women using an emergency contraceptive method must use back up protection for 1-2 weeks depending on method. The Copper-IUD is the most effective emergency contraceptive method. The investigators wish to explore if women choosing the Cooper IUD have a higher frequency of use of an effective contraceptive method 3 months and 6 months after the use of an emergency contraceptive method than women who choose to use the emergency contraceptive pill EllaOne (ulipristal acetate).

NCT ID: NCT02076217 Active, not recruiting - Contraception Clinical Trials

Quick Start of Highly Effective Contraception

Start date: February 2014
Phase:
Study type: Observational

This project will quantify rates of contraceptive failure when unprotected intercourse occurs 6-14 days prior to initiation of highly effective reversible contraceptives (such as IUD's and Implants).

NCT ID: NCT01963962 Completed - Clinical trials for Emergency Contraception

Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception

COLIEC
Start date: July 2013
Phase: N/A
Study type: Observational

The purpose of this study is to see how often women who come to a family planning clinic for emergency contraception, the morning after pill, are willing to use either the copper IUD or the levonorgestrel IUD. The investigators will also see if pregnancies occur in those choosing the levonorgestrel IUD and if people continue to use the IUD for 1 year.

NCT ID: NCT01569737 Completed - Clinical trials for Emergency Contraception

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

ellipseII
Start date: November 18, 2014
Phase:
Study type: Observational

The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.